Blebbistatin reveals beneficial effects on the cystometric parameters in an animal model of detrusor overactivity

Naunyn Schmiedebergs Arch Pharmacol. 2019 Jul;392(7):843-850. doi: 10.1007/s00210-019-01640-3. Epub 2019 Mar 9.

Abstract

The aims of the study were to determine the effectiveness of blebbistatin (BLEB) on detrusor overactivity (DO) in an animal model induced by retinyl acetate (RA) and, because of potential urothelial permeability, to evaluate the degenerative impact of BLEB on the urothelium. Three days after RA instillation into the urinary bladder, BLEB was administered into the bladder and immediately after cystometric assessment was performed. Furthermore, Evans Blue extravasation into bladder tissue and urothelium thickness were measured. Sixty female Wistar rats were used and randomly assigned to one of four groups (n = 15 in each group): (1) control, (2) RA, (3) BLEB, and (4) RA + BLEB. RA administration induced changes in cystometric parameters reflecting DO, as previously reported. Treatment with BLEB did not significantly alter cystometric parameters in rats which did not receive RA. Administration of BLEB to rats pretreated with RA reversed changes in cystometric parameters induced by RA in basal pressure, threshold pressure, detrusor overactivity index, amplitude of nonvoiding contractions, frequency of nonvoiding contractions, voided volume, volume threshold, intercontraction interval, bladder compliance, and volume threshold to elicit nonvoiding contractions. There were no significant differences in Evans Blue extravasation into bladder tissue or urothelium thickness between the groups. The current research provides new data on the possible utility of blebbistatin in the pharmacotherapy of DO, which is an important feature of overactive bladder (OAB). Further studies in human patients with DO/OAB are warranted to confirm these preclinical results.

Keywords: Blebbistatin; Cystometry; Detrusor overactivity; OAB; Rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravesical
  • Animals
  • Disease Models, Animal
  • Diterpenes
  • Female
  • Heterocyclic Compounds, 4 or More Rings / administration & dosage
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Rats, Wistar
  • Retinyl Esters
  • Urinary Bladder, Overactive / drug therapy*
  • Urination / drug effects
  • Urodynamics / drug effects*
  • Vitamin A / analogs & derivatives

Substances

  • Diterpenes
  • Heterocyclic Compounds, 4 or More Rings
  • Retinyl Esters
  • Vitamin A
  • blebbistatin
  • retinol acetate